Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane Multi-pass membrane protein |
Domain |
PF00173 Cytochrome b5-like Heme/Steroid binding domain PF00487 Fatty acid desaturase |
Function |
Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma-linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum. |
Biological Process |
GO:0001676 long-chain fatty acid metabolic process GO:0006631 fatty acid metabolic process GO:0006633 fatty acid biosynthetic process GO:0006636 unsaturated fatty acid biosynthetic process GO:0016053 organic acid biosynthetic process GO:0033559 unsaturated fatty acid metabolic process GO:0036109 alpha-linolenic acid metabolic process GO:0043651 linoleic acid metabolic process GO:0044283 small molecule biosynthetic process GO:0046394 carboxylic acid biosynthetic process GO:0072330 monocarboxylic acid biosynthetic process |
Molecular Function |
GO:0004768 stearoyl-CoA 9-desaturase activity GO:0016213 linoleoyl-CoA desaturase activity GO:0016215 acyl-CoA desaturase activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016717 oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water |
Cellular Component | - |
KEGG |
hsa03320 PPAR signaling pathway hsa00592 alpha-Linolenic acid metabolism hsa01040 Biosynthesis of unsaturated fatty acids hsa01212 Fatty acid metabolism |
Reactome |
R-HSA-2046105: Linoleic acid (LA) metabolism R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-2046104: alpha-linolenic (omega3) and linoleic (omega6) acid metabolism R-HSA-2046106: alpha-linolenic acid (ALA) metabolism |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FADS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FADS2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FADS2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FADS2 in various data sets.
|
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FADS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FADS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FADS2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FADS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FADS2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FADS2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FADS2 |
Name | fatty acid desaturase 2 |
Aliases | FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ...... |
Chromosomal Location | 11q12.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FADS2 collected from DrugBank database. |
Details on drugs targeting FADS2.
|